The bid is supported by 44.6% of shareholders, representing a bid premium of 74% compared with yeste...
Cantargia levererar ett positivt nyhetsflöde kring bolagets andra kliniska projekt, CAN10.
Redeye comments on the readout from the phase IIa study of naptumomab in combination with docetaxel ...
Fortsatta förhandlingar pågår med obligationsägarna för att nå en långsiktigt finansiell lösning, vi...
Redeye comments on Enviro’s Q1 report, which presented no real surprises.
Redeye provides a research update following the Q1 report published by Lipum earlier today.
Patientrekryteringen i mål I kvartalet inkluderades den sista patienten till bolagets pågående fas 1...
The company’s fundamentals are moving in the right direction while the gold market remains hot.
On the 23rd of May, ChromoGenics largest owner, Färna Invest, placed a takeover bid of SEK10 for the...
While the Capital Market Day, as expected, did not feature any new financial targets, Fortnox was ge...
Q1e: one Freemelt ONE delivery, SEK 4.9m sales, SEK -8.
Återhämtningen påbörjad Omsättning ökade med 9,3 procent, vilket främst var hänförligt till en stark...
Redeye gives its initial comment on the news that Kristina Torfgård has been appointed CEO of IRLAB.
On Friday, Ngenic press released that its board of directors had decided to apply for debt restructu...
I dag offentliggjorde edyoutec sin delårsrapport för kv1 2024.
Redeye comments on this morning's press release from Enviro, stating its current equity stake in the...
Trots en svag start på året bibehåller vi vår optimistiska syn inför andra halvåret 2024 och kommand...
SEK 100m run-rate sales contribution excl. sub-contractors Potential to earn 8-9% EBIT margin Acquir...
Redeye comments on Scandion Oncology’s Q1 2024 report, shortly after the company announced final ter...
Kvartalet påverkades negativt av förra årets starka avslutning.